Read the new KDIGO Direct for the latest news from KDIGO: https://t.co/SR7cXH8V13
In this issue:
- KDIGO publishes new reports on B Cell-Mediated Therapies and Green Dialysis Conference Carbon Footprint and Sustainability
- KDIGO launches new FSGS podcast series
- KDIGO at #ERA26
- New KDOQI US commentaries on KDIGO Guidelines
- New CME/CE activities
- Additional resources
💡 JAMA Insights: #GLP1 receptor agonists and dual incretin agents support weight loss with minimal lifestyle counseling, but diet and activity advice remain necessary for safety and long-term success in #Obesity care.
https://t.co/pByOSM0aZR
Disparity in the regulation and prevention of water versus sodium imbalance in heat-stress nephropathy: a phylogenetic perspective
https://t.co/havCsE6Zsb
PPT slides for the FIND-CKD primary presentation are now freely available - including the glomerular disease data & INFINITY (IPD meta-analysis).
Use them, adapt them, share them as you like
All FIND-CKD presentations & publications now live at https://t.co/Nh6uJ3kPZA
#ERA26
Now online in @NDTsocial by @P_Rossing
GLP-1ra in T2DM: CV protection versus ocular safety
🧐Rapid and substantial reductions of hyperglycemia may cause worsening of unstable diabetic retinopathy!
▶️https://t.co/gewsUExCzp
Pre-transplant and persistent post-transplant hyperparathyroidism and kidney transplant outcomes: a systematic review and meta-analysis
https://t.co/HeDBvj4gKw
Key factors for digital health researchers:
✅ Clear communication with participants
✅ Reliable access to required technology
✅ User-friendly design
✅ Simple, effective recruitment & screening
✅ Strong privacy & security protections
✅ Robust infrastructure
RESEARCH ARTICLE: Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics @JuliaBinder9 @erkan_uog @profAsmaKhalil
https://t.co/pMcxe8qenu
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)
finerenone reduced the risk of CKD progression, including kidney failure alone, and reduced HF hospitalisation, CV death, and all-cause death.